Theravance Biopharma, Inc. 4

Theravance Biopharma CFO Sawaf Aziz had 8,112 ordinary shares withheld at about $16.95 per share to cover taxes from RSU vesting, leaving him with 336,841 shares owned directly.

On 2026-08-20, Sawaf Aziz, SVP & Chief Financial Officer of Theravance Biopharma, Inc., had 8,112 ordinary shares withheld by the company at an implied price of approximately $16.95 per share to cover tax obligations arising from the vesting of previously granted restricted stock units. This is a routine, non-open-market transaction classified as a disposition to the issuer (code F), and following the withholding, Aziz directly owns 336,841 ordinary shares of Theravance Biopharma. The transaction does not represent a discretionary sale in the open market but rather automatic share withholding tied to equity compensation vesting.

Filing Facts

CIK

1583107

Ticker

TBPH

Form

4

Source Type

fda

Accession

0001961289-26-000008

Alert Tier

5